Anti-PD-1PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies
Joint Authors
Yang, Jiali
Liu, Xiaoming
Sui, Hongshu
Ma, Ningxia
Wang, Ying
Li, Hui
Su, Yanping
Source
Journal of Immunology Research
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-17, 17 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-08-08
Country of Publication
Egypt
No. of Pages
17
Main Subjects
Abstract EN
Lung cancer remains a leading cause of cancer-related mortality worldwide with the poor prognosis.
Encouragingly, immune checkpoint blockade targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) has dramatically changed the landscape for treatments in patients with non-small-cell lung cancer (NSCLC).
However, only a small proportion of NSCLC patients responded to monotherapy of anti-PD-1/PDL1 agents; together, the development of resistance to anti-PD-1/PD-L1 therapy that leads to failure of anti-PD-1/PD-L1 therapy has significantly limited a broad applicability of the findings in clinical practices.
Nowadays, several companion diagnostic assays for PDL1 expression have been introduced for identifying patients who may benefit the immunotherapy.
In addition, results from clinical trials explored combinatory therapeutic strategies with conventional and/or targeted therapy reported a higher efficacy with an acceptable safety profile in NSCLC treatments, as compared to the monotherapy of these agents alone.
In this review article, we summarized several anti-PD-1/PD-L1 agents licensed for NSCLC treatment, with a focus on predictive biomarkers and companion diagnostic assays for identification of NSCLC patients for immunotherapy anti-PD-1/PDL1 antibodies.
Of a great interest, potentials of the combinatory therapy of anti-PD-1/PDL1 therapy with a conventional or targeted therapy, or other immunotherapy such as CAR-T cell therapy were emphasized in the article.
American Psychological Association (APA)
Sui, Hongshu& Ma, Ningxia& Wang, Ying& Li, Hui& Liu, Xiaoming& Su, Yanping…[et al.]. 2018. Anti-PD-1PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. Journal of Immunology Research،Vol. 2018, no. 2018, pp.1-17.
https://search.emarefa.net/detail/BIM-1192906
Modern Language Association (MLA)
Sui, Hongshu…[et al.]. Anti-PD-1PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. Journal of Immunology Research No. 2018 (2018), pp.1-17.
https://search.emarefa.net/detail/BIM-1192906
American Medical Association (AMA)
Sui, Hongshu& Ma, Ningxia& Wang, Ying& Li, Hui& Liu, Xiaoming& Su, Yanping…[et al.]. Anti-PD-1PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. Journal of Immunology Research. 2018. Vol. 2018, no. 2018, pp.1-17.
https://search.emarefa.net/detail/BIM-1192906
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1192906